These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 28694672)
81. Partial treatment response to capmatinib in Lefler DS; Tierno MB; Bashir B Cancer Biol Ther; 2022 Dec; 23(1):112-116. PubMed ID: 35129063 [TBL] [Abstract][Full Text] [Related]
82. A Hepatocellular Carcinoma Patient with Shi HS; Wang S; Li MJ; Wu LQ Visc Med; 2021 Mar; 37(2):116-119. PubMed ID: 33981751 [TBL] [Abstract][Full Text] [Related]
83. Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy. Gao J; Fang Y; Chen J; Tang Z; Tian M; Jiang X; Tao C; Huang R; Zhu G; Qu W; Wu X; Zhou J; Fan J; Liu W; Shi Y Oncogene; 2023 Aug; 42(33):2507-2520. PubMed ID: 37420030 [TBL] [Abstract][Full Text] [Related]
84. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333 [TBL] [Abstract][Full Text] [Related]
85. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. Wang L; Zhu H; Zhao Y; Pan Q; Mao A; Zhu W; Zhang N; Lin Z; Zhou J; Wang Y; Zhang Y; Wang M; Feng Y; He X; Xu W; Wang L J Transl Med; 2020 Jul; 18(1):273. PubMed ID: 32631434 [TBL] [Abstract][Full Text] [Related]
86. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma. Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757 [TBL] [Abstract][Full Text] [Related]
87. Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3. Xu H; Luo W; Zhao Z; Miao X; Chai C; Hu J; Tang H; Zhang H; Zhou W Hum Cell; 2023 Mar; 36(2):854-865. PubMed ID: 36662372 [TBL] [Abstract][Full Text] [Related]
88. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial. Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424 [TBL] [Abstract][Full Text] [Related]
89. Ivosidenib Boosts OS in Cholangiocarcinoma. Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569 [TBL] [Abstract][Full Text] [Related]
91. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Param NJ; Bramel ER; Sia D Surg Pathol Clin; 2022 Sep; 15(3):529-539. PubMed ID: 36049834 [TBL] [Abstract][Full Text] [Related]
92. Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review. Wang LY; Gong S; Gao LP; Hou LX; He W Medicine (Baltimore); 2018 Dec; 97(49):e13372. PubMed ID: 30544406 [TBL] [Abstract][Full Text] [Related]
93. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma. Turpin A; Descarpentries C; Grégoire V; Farchi O; Cortot AB; Jamme P Oncologist; 2023 Jan; 28(1):80-83. PubMed ID: 36434677 [TBL] [Abstract][Full Text] [Related]
94. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. Rengan AK; Denlinger CS J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504 [TBL] [Abstract][Full Text] [Related]
95. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing. Stenzinger A; Vogel A; Lehmann U; Lamarca A; Hofman P; Terracciano L; Normanno N Cancer Treat Rev; 2024 Jan; 122():102649. PubMed ID: 37984132 [TBL] [Abstract][Full Text] [Related]
96. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998 [TBL] [Abstract][Full Text] [Related]
97. Distant supervision for imaging-based cancer sub-typing in Intrahepatic Cholangiocarcinoma. Savino MS; Cavinato L; Costa G; Fiz F; Torzilli G; Vigano L; Ieva F Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():1032-1035. PubMed ID: 36086172 [TBL] [Abstract][Full Text] [Related]
99. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. Schmitz KJ; Lang H; Wohlschlaeger J; Sotiropoulos GC; Reis H; Schmid KW; Baba HA World J Gastroenterol; 2007 Dec; 13(48):6470-7. PubMed ID: 18161916 [TBL] [Abstract][Full Text] [Related]
100. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. Yu X; Zhu L; Wang T; Chen J Front Immunol; 2023; 14():1037945. PubMed ID: 37138880 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]